Eli Lilly and Company has filed six new lawsuits against U.S. entities accused of selling unauthorized retatrutide products, escalating the pharmaceutical company’s efforts to combat what it describes as a growing black market for the investigational drug.
The company said it has also referred more than 200 individuals and entities to U.S. regulators, law enforcement agencies and professional licensing boards as part of a broader campaign against illegal retatrutide sales. Lilly is working with regulators, customs authorities and law enforcement agencies globally to disrupt the supply and distribution of products it says are being marketed unlawfully to consumers.
Retatrutide is an investigational molecule currently being evaluated in Phase 3 clinical trials for obesity, type 2 diabetes and other related conditions. The drug is designed to act on three metabolic pathways and is being studied for its potential to produce significant effects on weight and metabolic health.
However, no medicine containing retatrutide has been approved for human use by any regulatory authority worldwide. Lilly emphasized that retatrutide cannot legally be sold to consumers outside the authorized clinical development process.
The company said the lawsuits target a range of U.S. entities, including compounding pharmacies, medical spas and online sellers. Some sellers allegedly market products under labels such as “research-use only” despite promoting them for human consumption.
Lilly’s action comes amid growing concern over the online marketing of unapproved medicines and products associated with emerging weight-loss treatments. According to the U.S. Food and Drug Administration (FDA), unapproved drugs intended for human use can pose significant risks because their identity, quality, manufacturing conditions, potency and safety may not be verified.
Lilly cited FDA statements indicating that retatrutide cannot lawfully be compounded and that products marketed as research-use only may be of unknown quality and potentially harmful to consumers.
David A. Hyman, M.D., Lilly’s chief medical officer, said retatrutide is undergoing rigorous clinical investigation and that products being sold through unauthorized channels should not be considered legitimate medicines. The company stressed that the safety and efficacy of the investigational treatment can only be properly assessed through controlled clinical development and regulatory review.
According to Lilly, illegal sellers have promoted retatrutide through medical spas, wellness clinics and online businesses, sometimes presenting themselves as legitimate healthcare providers or suppliers. The company alleges that some products are manufactured by unregulated foreign facilities, creating additional concerns about their composition and quality.
The company said regulators and law enforcement agencies in various countries have already taken action against illegal drug networks, including conducting raids, intercepting shipments and making arrests connected with clandestine manufacturing and distribution operations.
Lilly has also reported more than 14,000 websites, advertisements, social media posts and product listings allegedly marketing retatrutide unlawfully. These reports have been submitted to internet service providers, social media platforms and e-commerce companies across more than 100 countries.
Despite these efforts, Lilly said some platforms continue to host or amplify misleading marketing content that could reach consumers seeking weight-loss treatments.
The six lawsuits filed by Lilly include cases against Aesthetic Envy Cosmetic Centers, Astra Peptides, Legendary Peptides, Striker Pharmacy, Texas Peptides and Lone Star Peptide Co. The cases have been filed in federal courts across California and Texas.
Beyond legal action, Lilly is calling on companies involved in the infrastructure supporting online commerce to take additional measures. The pharmaceutical company is urging social media and e-commerce platforms to prevent illegal retatrutide advertising and sales, while also asking credit card companies, payment processors, shipping companies and logistics providers to disrupt transactions and distribution associated with unauthorized products.
Lilly is also encouraging healthcare providers to educate patients about the potential risks of purchasing unapproved retatrutide. The company said consumers can assist enforcement efforts by reporting suspected illegal products to appropriate regulators and law enforcement authorities.
The legal campaign underscores the growing commercial interest surrounding investigational metabolic medicines and the challenges pharmaceutical companies and regulators face in controlling unauthorized sales before products receive regulatory approval.
For Lilly, the lawsuits represent another component of its effort to protect the integrity of retatrutide’s clinical development program and prevent consumers from being exposed to products whose safety, composition and effectiveness have not been established through regulatory review.
Retatrutide remains an investigational medicine, and Lilly’s Phase 3 studies will determine whether the candidate can demonstrate sufficient safety and efficacy to support potential regulatory applications in the future.